Bhushan S. Pattni,† Vladimir V. Chupin,‡ and Vladimir P. Torchilin*,†,§,∥ †Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, Massachusetts 02115, United States ‡Laboratory for Advanced Studies of Membrane Proteins, Moscow Institute of Physics and Technology, Dolgoprudny 141700, Russia Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia

New Developments in Liposomal Drug Delivery.

The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes. Further evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype.

TFOS DEWS II Management and Therapy Report

Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review.

Particle size and physical state of the lipid phase are major factors influencing the permanence of lipid dispersions. Nanostructured lipid carriers (NLC) are a delivery system in which partial-crystallized lipid particles with mean radii ≤ 100 nm are dispersed in an aqueous phase containing emulsifier(s), as a potential delivery system may have some advantages in certain circumstances when compared with other colloidal carriers. NLC are a useful nutraceutical delivery system with high drug loading, encapsulation efficiency and stability. They may increase, bioavailability and stability of bioactive compounds, and shelf-life, consumer acceptability, functionality, nutritional value and safety of food systems, and provide controlled release of encapsulated materials. In this review, beneficial aspects of NLC are presented and valuable information about ingredients, production methods, structure and characteristics of them provided. Moreover, potential applications and disadvantages of NLC as emerging delivery system in food science are introduced. Industrial relevance With the increasing public perception of a strong correlation between food and disease prevention, producers are trying to enrich staple foods and beverages with nutraceuticals and produce functional foods. Nonetheless, fortification of aqueous-based food with many of nutraceuticals is greatly limited owing to their poor water-solubility, chemical instability, and low bioavailability. NLC are a novel nanocarrier that may dispel these limitations, combine the advantages of other lipid nanocarriers and avoid some of their disadvantages. They may be suitable for application within foods and transparent/opaque beverages.

Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules

Nanostructured lipid carriers: Promising drug delivery systems for future clinics.

The invention belongs to the technical field of medicine, and relates to a preparation method and application of tanshinone II A solid dispersion pellets. The in-vitro dissolution rate of the tanshinone II A solid dispersion pellets prepared by a fluidized bed one-step molding process is remarkably increased, and bioavailability is remarkably improved; and the process is convenient to operate, feasible, high in production efficiency and low in cost, and industrial production is easy to realize.

Preparation method and application of tanshinone II A solid dispersion pellets

Theoretical modeling and dynamic characteristics analysis of piezoelectric inertial actuator

Evaluation of pharmacokinetics and pharmacodynamics relationships for Salvianolic Acid B micro-porous osmotic pump pellets in angina pectoris rabbit

The purpose of this study was to develop the novel naproxen/esomeprazole magnesium compound pellets (novel-NAP/EMZ) depending on EMZ acid-independent mechanism which has been proved to be predominate in the mechanism of co-therapy with nonsteroidal anti-inflammatory drug. The novel-NAP/EMZ compound pellets, composed of NAP colon-specific pellets (NAP-CSPs) and EMZ modified-release pellets (EMZ-MRPs), were prepared by fluid-bed coating technology with desired in vitro release profiles. The resulting pellets were filled into hard gelatin capsules for in vivo evaluation in rats and compared with the reference compound pellets, consisted of NAP enteric-coated pellets (NAP-ECPs) and EMZ immediate-release pellets (EMZ-IRPs). The reference compound pellets were prepared simulating the drug delivery system of VIMOVO®. In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0–t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 ± 0.12 h) than that of IRPs (1.4...

Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation

Development of sustained-release pellets to modulate the in vivo processes of the main active components of Danshen: A pharmacokinetic and pharmacodynamic evaluation.

Jianping Liu

Papers

Preparation method and application of tanshinone II A solid dispersion pellets

Theoretical modeling and dynamic characteristics analysis of piezoelectric inertial actuator

Evaluation of pharmacokinetics and pharmacodynamics relationships for Salvianolic Acid B micro-porous osmotic pump pellets in angina pectoris rabbit

Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation

Development of sustained-release pellets to modulate the in vivo processes of the main active components of Danshen: A pharmacokinetic and pharmacodynamic evaluation.